Welcome to METHIV
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus lacinia odio vitae vestibulum vestibulum. Cras venenatis euismod malesuada.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus lacinia odio vitae vestibulum vestibulum. Cras venenatis euismod malesuada.
The safety of new weight loss drugs for people with HIV is being investigated, focusing on potential interactions with antiretroviral therapy and ensuring they do not compromise HIV treatment efficacy or overall health
Read moreSwitching from tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in HIV treatment results in modest weight loss and improvements in cholesterol and triglyceride levels.
Read moreWeight gain associated with HIV treatments, particularly those using integrase inhibitors, is more complex than previously thought, prompting further research into drug-specific effects.
Read moreThe weight loss drug semaglutide may improve health outcomes for people with HIV by reducing weight and addressing obesity-related health issues, according to MUSC researchers.
Read moreSwitching to an integrase inhibitor during menopause is linked to significant weight gain in women with HIV, particularly affecting visceral fat and body mass index.
Read moreStudies presented at CROI 2024 show significant benefits of semaglutide for weight loss and metabolic health in people with HIV, though access to the drug remains limited due to high demand and cost.
Read moreMore significant weight gain during pregnancy in women with HIV, especially with dolutegravir-based treatment, is associated with reduced risk of adverse birth outcomes such as premature birth and stillbirth.
Read moreA Kaiser Permanente study found that people with HIV starting antiretroviral treatment (ART) experienced greater weight gain over two years compared to those without HIV, with weight gain varying by ART medication class and typically stabilizing after the initial period.
Read moreRecent antiretroviral therapy (ART) has been linked to unhealthy weight gain, particularly affecting women and black populations, posing new clinical challenges in managing obesity among people living with HIV.
Read moreManaging weight with HIV treatment is crucial, as treatments can lead to both weight loss and gain. Balancing a healthy diet and regular exercise can help maintain optimal weight and improve overall health.
Read moreWeight gain is a common issue for people on HIV treatment, particularly with antiretroviral therapy, and managing this side effect is crucial for overall health and treatment efficacy.
Read moreNew weight-loss drugs like semaglutide and tirzepatide appear safe and effective for people living with HIV, offering significant benefits for managing weight and related health complications, although more research is needed.
Read moreStudies indicate that weight-loss drugs like semaglutide and tirzepatide are safe and effective for people living with HIV, offering significant benefits for weight management and reducing metabolic complications.
Read moreSemaglutide, a GLP-1 agonist, has shown promise in managing weight, muscle mass, and lipoatrophy in people living with HIV, as presented at IDWeek 2023, highlighting its potential benefits in this population.
Read moreGreater weight gain in the first year of HIV treatment increases the risk of diabetes, metabolic syndrome, and precursors of heart disease, with variations in risk based on race and sex.
Read moreSwitching away from integrase inhibitors does not reverse weight gain in people with HIV, as studies have shown continued weight gain with alternative regimens.
Read moreStudies indicate that weight gain linked to HIV treatment is influenced by factors like changes in fat metabolism and the gut microbiome, with newer drugs such as TAF and integrase inhibitors often causing more weight gain.
Read morePeople with HIV starting integrase strand transfer inhibitors (INSTIs) may experience weight gain, but a two-year study shows a subsequent stabilization in weight, providing a reprieve from initial increases.
Read morePeople with advanced HIV who start antiretroviral treatment experience greater weight gain compared to those who begin treatment with higher CD4 counts, with integrase inhibitors and tenofovir alafenamide being significant contributors.
Read moreA French study found that initiating HIV treatment early significantly reduces the extent of weight gain compared to starting treatment later, suggesting early treatment initiation can mitigate excessive weight gain associated with antiretroviral therapy.
Read moreWeight loss after switching from tenofovir alafenamide (TAF) and an integrase inhibitor is more likely in individuals with higher body mass index (BMI), especially those classified as clinically obese.
Read moreA Dutch study found that switching to HIV treatments including tenofovir alafenamide (TAF) and integrase inhibitors significantly increased the risk of weight gain, especially among women, younger individuals, and those who had lost weight prior to the switch.
Read moreWeight gain linked to antiretroviral therapy is a significant concern for people with HIV, with certain treatments causing more pronounced increases in body weight, necessitating careful management and monitoring of treatment regimens to mitigate these effects.
Read moreCabenuva, a long-acting injectable HIV treatment, effectively suppresses HIV regardless of body weight, though longer needles may be needed for individuals with obesity to ensure proper administration.
Read morePeople with HIV on antiretroviral treatment gain weight faster than HIV-negative individuals, with the rate of weight gain being three times higher and resulting in a higher body mass over a 12-year follow-up period.
Read moreSwitching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) results in rapid weight gain, regardless of other HIV drugs taken.
Read morePopular anti-HIV drugs, particularly integrase inhibitors, have been linked to significant weight gain in some women, equivalent to what would typically be expected over a decade, occurring within just two years of treatment.
Read moreHIV-related immune activation may predict weight gain and worsen health complications, particularly in women, even with effective antiretroviral therapy.
Read more